Landos Biopharma, Inc.
Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
Last updated:
Abstract:
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.
Status:
Grant
Type:
Utility
Filling date:
16 Nov 2018
Issue date:
14 Dec 2021